Conclusions
Antimyosin studies provide sensitive, noninvasive means for detection of myocardial cell damage and constitute an alternative to endomyocardial biopsy. In some cases (cardiac rejection and cardiomyopathy), antimyosin studies are more sensitive than endomyocardial biopsy (sampling error or myocardial damage not related to myocarditis).
Traditionally, the impact of several agents (e.g., rejection, infection, and drugs) on the myocardium has been evaluated through the presence or absence of functional ventricular abnormalities. Antimyosin studies in various settings have revealed that detectable myocardial cell damage may coexist with normal ventricular function. Therefore the possibility of independently assessing the presence of myocardial damage by antimyosin opens the possibility to a more accurate and early detection of myocardial involvement.
Article PDF
Avoid common mistakes on your manuscript.
References
Khaw BA, Narula J. Antibody imaging in the evaluation of cardiovascular diseases. J Nucl Cardiol 1994;1:457–76.
Wallwork J, Cory-Pearce R, English TAH. Cyclosporine for cardiac transplantation: UK trial. Transplant Proc 1983; 15(suppl):3135–41.
Oyer PE, Stinson EB, Jamieson SW, et al. Cyclosporin-A in cardiac allografting: a preliminary experience. Transplant Proc 1983;15:1247–52.
Kriett JM, Kaye MP. The Registry of the International Society for Heart Transplantation: seventh official report, 1990. J Heart Transplant 1990;9:323–30.
Billingham ME. Diagnosis of cardiac rejection by endomyocardial biopsy. Heart Transplant 1981;1:25–30.
Stovin PGI The morphology of myocardial rejection and transplantation pathology. In: Calne RY, ed., Transplantation immunology. Oxford: Oxford University Press, 1984: 78–100.
Pomerance A, Stovin PGI Heart transplant pathology: the British experience. J Clin Pathol 1985;38:146–59.
Ballester M, Carrió I, Abadal ML, Obrador D, Bernà L, Caralps-Riera JM. Patterns of evolution of myocyte damage after human heart transplantation detected by indium 111 monoclonal antimyosin. Am J Cardiol 1988;62:623–7.
Carrió I, Berná L, Ballester M, et al. Indium-111 antimyosin scintigraphy to assess miocardial damage in patients with suspected myocarditis and cardiac rejection. J Nucl Med 1988;29:1893–900.
Ballester M, Obrador D, Carrió I, et al. 111In-monoclonal antimyosin antibody studies after the first year of heart transplantation: identification of risk groups for developing rejection during long-term follow-up and clinical implications. Circulation 1990;82:2100–8.
Ballester M, Obrador D, Carrió I, et al. Early postoperative reduction of monoclonal antimyosin antibody uptake is associated with absent rejection-related complications after heart transplantation. Circulation 1992;85:61–8.
Hosenpud JD. Noninvasive diagnosis of cardiac allograft rejection: another of many searches for the grail. Circulation 1992;85:368–71.
Roitt I, Brostoff J, Male D. Transplantation and rejection. In: Roitt I, Brostoff J, Male D, eds. Immunology. London: Gower Medical Publishing, 1985:24.1–10.
Yasuda T, Palacios IF, Dec W, et al. Indium 111-monoclonal antimyosin antibody imaging in the diagnosis of acute myocarditis. Circulation 1987;76:306–11.
Dec GW, Palacios I, Yasuda T, et al. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol 1990;16:97–104.
Narula J, Khaw BA, Dec GW et al. Recognition of acute myocarditis masquerading as acute myocardial infarction. N Engl J Med 1993;328:100–4.
Obrador D, Ballester M, Carrió I, Bernà L, Pons G. High prevalence of ongoing myocyte damage in patients with chronic dilated cardiomyopathy. J Am Coll Cardiol 1989;13:1289–93.
Obrador D, Ballester M, Carrió I, et al., Active myocardial damage without attending inflammatory response in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1993;21: 1667–71.
Obrador D, Ballester M, Carrió I, et al. Presence, evolving changes, and prognostic implications of myocardial damage detected in idiopathic and alcoholic dilated cardiomyopathy by 111In monoclonal antimyosin antibodies. Circulation 1994;89:2054–61.
Why HJF, Meany BT, Richardson PJ, et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994;89:2582–9.
Schwartz RG, Mckenzie MB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Med 1987;82:1109–18.
Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia in childhood. N Engl J Med 1991;324:808–15.
Estorch M, Carrió I, Berná L, et al. 111In antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med 1990;12:1965–70.
Carrió I, Estorch M, Berná L, et al. Assessment of anthracycline-induced myocardial damage by quantitative indium-111 myosin-specific monoclonal antibody studies. Eur J Nucl Med 1991;18:806–12.
Carrió I, Estorch M, Berná L et al. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med 1993;34: 1503–7.
Jain D, Zaret B. Antimyosin cardiac imaging: will it play a role in the detection of doxorubicin cardiotoxicity? J Nucl Med 1990;12:1970–4.
Narula J, Strauss HW, Khaw BA. Antimyosin positivity in doxorubicin cardiotoxicity: earlier than the conventional evidence. J Nucl Med 1993;34:1507–9.
Martí V, Ballester M, Udina C, Obrador D, Carrió I. Evaluation of myocardial cell damage by indium 111-antimyosin antibodies in patients under chronic tricyclic antidepressant drug treatment. Circulation (in press).
Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients Am J Cardiol 1987;60:1340–55.
Diaz RA, Obasohan A, Oakley CM. Prediction of outcome in dilated cardiomyopathy. Br Heart J 1987;58:393–9.
Urbano-Marquez A, Estruch R, Navarro-Lopez F et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989;320:409–15.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carrió, I., Ballester, M. Clinical future of antimyosin imaging in noncoronary heart disease. J Nucl Cardiol 2, 155–158 (1995). https://doi.org/10.1016/S1071-3581(95)80027-1
Issue Date:
DOI: https://doi.org/10.1016/S1071-3581(95)80027-1